Log in

Relevant bibliographies by topics / CESAR Central European Society for Anticancer Drug Research / Journal articles

To see the other types of publications on this topic, follow the link: CESAR Central European Society for Anticancer Drug Research.

Journal articles on the topic 'CESAR Central European Society for Anticancer Drug Research'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 17 journal articles for your research on the topic 'CESAR Central European Society for Anticancer Drug Research.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Dittrich, C., and B. Keppler. "Central European Society for Anticancer Drug Research (CESAR)." Oncology Research and Treatment 23, no. 5 (2000): 492–93. http://dx.doi.org/10.1159/000027220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dittrich, C., M. Gneist, A. Zandvliet, C. Johnston, and M. Yule. "431 Phase I and pharmacokinetic study of indisulam (E7070) in combination with carboplatin, a CESAR Central European Society for Anticancer Drug Research — EWIV report." European Journal of Cancer Supplements 2, no. 8 (2004): 129. http://dx.doi.org/10.1016/s1359-6349(04)80439-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hartung, G. "Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research EWIV (CESAR)." Int. Journal of Clinical Pharmacology and Therapeutics 42, no. 11 (2004): 631. http://dx.doi.org/10.5414/cpp42631.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Steinbild, S., K. Mross, D. Morant, et al. "Phase II study of Sorafenib (BAY 43–9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research—EWIV (CESAR)." Journal of Clinical Oncology 24, no. 18_suppl (2006): 3094. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3094.

Full text

Abstract:

3094 Background: Sorafenib (BAY 43–9006) is a novel, orally active multi-kinase inhibitor with anti-angiogenic and anti-proliferative activity, blocking both Raf/MEK/ERK pathway and receptor tyrosine kinases VEGFR-2 and PDGFR. Activity of sorafenib in hormone-refractory progressive patients (pts) with prostate cancer (PC) was investigated in a Phase II clinical study. Methods: Pts received sorafenib 400 mg bid by continuous oral dosing. Pts with progressive disease during hormonal treatment and no prior chemotherapy therapy for advanced prostate cancer, and either one uni-dimensional measurabl

APA, Harvard, Vancouver, ISO, and other styles

5

Richly, Heike, Luise Maute, Gerhard Heil, et al. "Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV." Journal of Clinical Oncology 31, no. 15_suppl (2013): 4035. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4035.

Full text

Abstract:

4035 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours, but PDAC is still associated with a poor prognosis in advanced disease with an overall 5-year survival of only about 15%. Therefore there is a need for new treatment strategies. To improve the standard therapy with gemcitabine we initiated a prospective randomized phase-II trial with gemcitabine (GEM) vs. gemcitabine plus sunitinib (SUNGEM) based on data of in vitro trials and phase-I data for the combination treatment. Methods: Patients (N=113) with locally advanced or metastatic PDAC were pr

APA, Harvard, Vancouver, ISO, and other styles

6

Steinbild, S., K. Mross, A. Frost, et al. "A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV." British Journal of Cancer 97, no. 11 (2007): 1480–85. http://dx.doi.org/10.1038/sj.bjc.6604064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hofheinz, R. D., C. Porta, G. Hartung, et al. "BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR)." Investigational New Drugs 23, no. 4 (2005): 363–68. http://dx.doi.org/10.1007/s10637-005-1445-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Keppler, B. K. "Annual Meeting of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR) during the Symposium ?Novel Approaches for the Discover." Int. Journal of Clinical Pharmacology and Therapeutics 43, no. 12 (2005): 566. http://dx.doi.org/10.5414/cpp43566.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hofheinz, R. D., C. Dittrich, M. A. Jakupec, et al. "Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EW." Int. Journal of Clinical Pharmacology and Therapeutics 43, no. 12 (2005): 590–91. http://dx.doi.org/10.5414/cpp43590.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Dittrich, C., A. Hochhaus, S. Schaad, et al. "Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV." Journal of Clinical Oncology 23, no. 16_suppl (2005): 3205. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3205.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Bergmann, L., V. Grünwald, L. Maute, et al. "2617 A Prospective Randomized Phase-II Trial with Temsirolimus vs. Sunitinib in non-clear Renal Cell Carcinoma. A Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and Interdisciplinary Renal Cell Carcinoma Group of the German Cancer Society (IAGN)." European Journal of Cancer 51 (September 2015): S517. http://dx.doi.org/10.1016/s0959-8049(16)31435-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Mross, K., C. Dittrich, W. E. Aulitzky, et al. "A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network." British Journal of Cancer 107, no. 2 (2012): 280–86. http://dx.doi.org/10.1038/bjc.2012.257.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Bergmann, Lothar, Viktor Grünwald, Luise Maute, et al. "A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society." Oncology Research and Treatment 43, no. 7-8 (2020): 333–39. http://dx.doi.org/10.1159/000508450.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Mross, Klaus, Max E. Scheulen, Thomas Licht, et al. "Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR)." Anti-Cancer Drugs 15, no. 1 (2004): 15–22. http://dx.doi.org/10.1097/00001813-200401000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Miller, Kurt, Rudolf Morant, Arnulf Stenzl, Ivan Zuna, and Manfred Wirth. "A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium." Urologia Internationalis 96, no. 1 (2015): 5–13. http://dx.doi.org/10.1159/000381589.

Full text

Abstract:

Introduction: This phase II trial evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib, in combination with first-line chemotherapy in advanced urothelial cancer. Methods: Chemotherapy-naïve patients with advanced or metastatic urothelial carcinoma were randomized 1:1:1 to receive six cycles of chemotherapy (gemcitabine 1,250 mg/m2 on days 1 and 8, and cisplatin 70 mg/m2 on day 1 of every cycle) concomitantly with gefitinib 250 mg/day (arm A); or with sequential gefitinib (arm B); or alone (arm C). The primary endpoint was the ti

APA, Harvard, Vancouver, ISO, and other styles

16

Choueiri, Toni K., Jens Bedke, Jose A. Karam та ін. "Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)." Journal of Clinical Oncology 41, № 6_suppl (2023): TPS748. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps748.

Full text

Abstract:

TPS748 Background: Treatment with the PD-1 inhibitor pembro produced significant improvement in disease-free survival after surgery for patients (pts) with ccRCC in the phase 3 KEYNOTE-564 trial. Based on these results, pembro was approved by the US Food and Drug Administration and the European Medicines Agency for adjuvant treatment of pts with RCC at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. Despite advances in the treatment landscape for RCC, more effective adjuvant treatment strategies are needed for pts at risk of recu

APA, Harvard, Vancouver, ISO, and other styles

17

Dolomatov, S.I., та W. Zukow. "Эпигенетика почек = Kidneys epigenetics". 7 липня 2019. https://doi.org/10.5281/zenodo.3270754.

Full text

Abstract:

<strong>Dolomatov S.I., Zukow W. </strong><strong>Эпигенетика почек</strong><strong> = Kidney</strong><strong>s</strong><strong> epigenetics</strong><strong>. </strong><strong>RSW. Radom,</strong><strong> 144 </strong><strong>p. ISBN </strong><strong>9780359774524</strong><strong>.</strong><strong> DOI </strong><strong>http://dx.doi.org/10.5281/zenodo.3270699</strong><strong> PBN Poland </strong><strong>https://pbn.nauka.gov.pl/sedno-webapp/works/917606</strong>           <strong>Radomska Szkoła Wyższa w Radomiu, Radom, Poland</strong>         &nbsp

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!